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Abstract
The latest advances concerning drug design and chemotherapy development to combat 
the Chagas’ disease are discussed. This chapter is based on the metabolic differences 
between the pathogenic parasite and mammal hosts that led to the progress in the search 
for novel metabolic pathways in parasites that may be essential for parasite’s survival but 
with no counterpart in the host. There is a considerable amount of work in the search of 
more promising molecular targets for drug design. However, the chemotherapy for this 
disease remains unsolved. It is based on old and fairly not specific drugs associated with 
long-term treatments, severe side effects, drug resistance, and different strains’ suscep-
tibility. Herein, a thorough analysis of selected molecular targets is described in terms 
of their potential usefulness for drug design. Therefore, rational approaches to the che-
motherapeutic control of American trypanosomiasis describing some useful metabolic 
pathways are covered. Enzymes involved in ergosterol biosynthesis (squalene synthase, 
HMG-CoA reductase, farnesyl diphosphate synthase (FPPS), sterol 24-methyltransferase, 
and sterol 14α-demethylase), trypanothione system (glutathionyl-spermidine synthe-
tase, trypanothione synthetase, and trypanothione reductase), cysteine proteases, trans-
sialidase, and so on are discussed. The design of specific inhibitors of these metabolic 
activities as possible means of controlling the parasites without damaging the hosts is 
presented.
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1. Introduction
Chagas’ disease or American trypanosomiasis is among the most prevalent parasitic dis-
eases worldwide [1–3]. It has been estimated that around 20 million people are infected and 
over 40 million individuals are facing the risk of infection by the hemoflagellates protozoan 
Trypanosoma cruzi, the responsible agent of Chagas’ disease. This disease is endemic in Latin 
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American countries, but the migration of individuals and blood transfusions have made pos-
sible the occurrence of the Chagas’ disease in developed countries. Currently, no vaccine is 
available, so the control of the disease is limited to its detection, vector control, screening of 
blood banks and organ donors, and case finding of infected pregnant women. Moreover, the 
development of a safer and more effective chemotherapeutic intervention is crucial for the 
treatment of Chagas disease.
This disease is characterized by three phases: (1) an early acute phase in which trypomasti-
gotes circulate in blood and infect cells transforming into the asexually-multiplying amasti-
gotes; (2) a subsequent intermediate phase where the cells are broken, parasites are released 
to the blood and infect other cells (in this phase there are unspecific symptoms like fever, 
allergic reactions, acute heart failure, or meningoencephalitis); (3) a late chronic phase, a 
prolonged, and asymptomatic indeterminate phase, where parasites establish in their target 
organs (during this stage patients may have nonspecific clinical manifestations or present 
major complications such as cardiomyopathy and/or megaesophagus and megacolon syn-
dromes [4]. The absence of adequate treatment in the acute phase results in the development 
of the above-mentioned stages of the disease.
The existing chemotherapy remains deficient; it is based on two old drugs empirically discov-
ered, (1) nifurtimox, actually discontinued, and (2) benznidazole (Figure 1). Although both 
of these compounds are able to cure at least 50% of recent infections, they present important 
drawbacks such as selective drug sensitivity on different T. cruzi strains, serious side effects 
including vomiting, anorexia, peripheral neuropathy, allergic dermopathy, and long-term 
treatment [2, 5, 6]. Moreover, these compounds are not effective in the chronic stage of the dis-
ease. Consequently, the development of novel, safe, and affordable compounds with potent 
antiparasitic activity is urgently needed [7, 8]. The existence of T. cruzi populations naturally 
resistant to benznidazole and nifurtimox led to the search for compounds with a different 
mechanism of action [2, 8]. The development of new drugs that are more effective and safer 
than those currently available is urgently necessary.
There is a considerable amount of work in the search of unique aspects of the biochemistry 
and physiology of T. cruzi intending to find specific molecular targets for drug design [9]. It 
can be thought that the selective inhibition of a biosynthetic pathway that leads to a crucial 
metabolite for parasite survival would not have any significant toxic effect on the host. Based 
on these facts, this chapter will discuss the search for new approaches based on metabolic 
differences between the pathogenic parasite and mammal hosts and the development of new 
potential antiparasitic drugs in the last years.
Figure 1. Drugs currently used for Chagas’ disease treatment.
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2. Molecular targets
There are many metabolic pathways and enzymes unique to Trypanosoma cruzi that constitute 
excellent molecular targets for drug development. However, despite the specificity of new 
compounds targeting parasite molecules, the effect of these drugs on mammalian metabolism 
must be carefully evaluated. A few of the most studied compounds targeting specific T. cruzi 
enzymes will be reviewed here.
2.1. Sterol biosynthesis
Isoprenoid biosynthetic pathway constitutes one of the most important metabolic pathways 
of all organisms because isoprenoids are essential for numerous biochemical functions. In 
trypanosomatides diverse enzymes of this biosynthetic pathway are involved in key process. 
Sterol biosynthesis in parasites differs from that in mammalian hosts since the final product is 
ergosterol instead cholesterol, the main sterol present in the mammals. As T. cruzi is entirely 
dependent on endogenously produced sterols for survival and proliferation, the sterol bio-
synthetic pathway constitutes an attractive target for drug development.
Reduction of endogenous sterols induces inhibition of the multiplication of T. cruzi. Then, 
the restriction of an enzyme of this biosynthetic pathway will inhibit the growth of the 
parasite [10, 11]. Sterol composition in T. cruzi is very similar to fungi with ergosterol and 
24-ethylergosterol being the primary mature sterols in the epimastigote stage. Fungisterol 
and 24-ethylfurgisterol are the major sterols produced by the amastigote stage. In conse-
quence, antifungal drugs are potentially capable of decreasing pathogen growth.
There are several interesting enzymes in the pathway as potential targets for anti-trypano-
somal chemotherapy. For example, sterol 14α-demethylase, sterol 24-methyltransferase, 
farnesyl diphosphate synthase, squalene synthase, and HMG-CoA reductase.
2.1.1. Sterol 14α-demethylase (CYP51)
Sterol 14α-demethylase is a CYP monooxygenase that catalyzes the removal of the 14α-methyl 
group from eburicol. Unlike other hemoproteins, the hemo cofactor in CYP51 is coordinated 
to cysteine residue instead of histidine. Since it is an essential enzyme in sterol biosynthesis, 
the activity inhibition could be lethal in organisms requiring sterols for membrane function 
[12]. This enzyme constitutes an interesting target as it has the advantage of being inhibited 
by antifungal agents currently in clinical use. Azoles are the most efficient antifungal drugs 
and there have been reported numerous examples of its antiparasitic effects [13–15].
The first azoles such as ketoconazole (3), miconazole (4), or fluconazole (5) (Figure 2) were 
found to have potent in vitro activity but did not cure the T. cruzi infection. The mechanism 
of action involves binding to T. cruzi CYP51 and a disruption of sterol biosynthesis resulting 
in accumulation of 14-methylated sterols [16]. New azole drugs developed to combat fungal 
infections have been evaluated for the activity against T. cruzi. The experimental azole drug 
D0870 (6) was the first to cure the chronic infection in mice [17]. Unfortunately, D0870 was 
discontinued as an antifungal agent due to undesired side effects.
New Approaches for Chagas’ Disease Chemotherapy
http://dx.doi.org/10.5772/intechopen.77235
155
Among second-generation azoles, posaconazole (7) is the most potent drug against T. cruzi; 
because of its broad-spectrum antifungal activity, it could potentially be repurposed for use 
in Chagas’ disease (Figure 2) [14]. It has been demonstrated that posaconazole is curative in 
the chronic murine model. In addition, it has potent activity against benznidazole and nifur-
timox resistant T. cruzi strains [18]. Recently, a case was reported in Spain, describing the cure 
of chronic infection by treatment with posaconazole in an immunosuppressed patient. This 
compound is currently in phase II clinical trial for Chagas’ disease. [19, 20] Unfortunately, 
posaconazole is a very expensive drug, so its application becomes impractical for patients 
with limited resources.
Ravuconazole (8) is another azole antifungal drug that has been evaluated as an antiparasitic 
agent and it appeared to be very efficient in restraining the parasitemia in vitro against T. cruzi 
in murine models [21]. However, since the half-life is much longer in humans than in mice, it 
is possible that this drug has curative effects. In fact, a prodrug of ravuconazole (E1224 9) is in 
a phase II trial [20]. In addition, ravuconazole has a simpler chemical structure than posacon-
azole, so the cost might be lower (Figure 2).
Tipifarnib (10) is an antitumor agent inhibiting human protein farnesyl transferase (Figure 2). 
It has considerable in vitro activity against T. cruzi. It was determined that the drug produces 
restriction of sterol biosynthesis by inhibition of CYP51 [22]. Analogs of tipifarnib have been 
designed and synthesized with improved CYP51 inhibitory activity and excellent pharmaco-
kinetic properties [23].
2.1.2. Sterol 24-methyltransferase (24-SMT)
This enzyme catalyzes the methenylation of zymosterol, an important step for the bio-
synthesis of ergosterol and other related 24-alkylated sterols, which are the main sterols 
Figure 2. Structures of sterol 14α-demethylase (CYP51) inhibitors.
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found in cell membranes of T. cruzi [24]. Azasterols are sterol compounds containing a 
nitrogen atom in the positions 23, 24, or 25 of the side chain. It was reported that these 
compounds inhibit the enzyme 24-SMT and demonstrated antiproliferative effects against 
trypanosomatids. 22, 26-azasterol (AZA, 11), and 24, 25-epiminolanosterol (EIL, 12) were 
the first azasterols reported to have trypanocidal activity [24, 25]. Different azasterols with 
modifications on their basic structure have been designed, synthesized, and biologically 
evaluated as antiparasitic agents [26, 27]. An important observation to take into account is 
that the 3β-OH group must be acylated. On the other hand, the nitrogen atom in the side 
chain can be located at the 23–25 position. The side chain can be attached via amine or 
amide bond and the presence of an ester moiety increased the activity [27]. General struc-
tures (13) of compounds, which have been developed as inhibitors of 24-SMT are shown 
in Figure 3.
2.1.3. 3-Hydroxy-3-methyl-glutaryl-coenzyme a reductase (HMG-CoA reductase)
The enzyme HMG-CoA reductase is involved in the first step in the pathway of isopren-
oid biosynthesis and catalyzes the reduction of 3-hydroxy-3-methyl-glutaryl-coenzyme A to 
mevalonate. Therefore, HMG-CoA reductase is a key enzyme and constitutes a valid molecu-
lar target since its inhibition will also prevent the synthesis of compounds of the mevalonate 
pathway.
Current cardiovascular drugs have been tested for the treatment of Chagas’ disease but new 
therapeutic drugs based on statins with a new anti-inflammatory approach have arisen as 
potential antiparasitic agents. Statins are thought to be associated with their ability to reduce 
cholesterol synthesis [28]. It was observed that lovastatin (14) and simvastatin (15) (Figure 4) 
have inhibited the growth of epimastigotes of T. cruzi and simvastatin could potentially 
inhibit HMG-CoA reductase both in epimastigotes and trypomastigotes [29]. Moreover, the 
combination of lovastatin with ketoconazole allowed the elimination of the presence of para-
sites into the blood flow and, in this way, prevented host death [30].
2.1.4. Farnesyl diphosphate synthase (FPPS)
The enzyme farnesyl pyrophosphate synthase, also known as farnesyl diphosphate synthase 
(FPPS) belongs to the E-family of the prenyltransferases and it has a key role in the isoprenoid 
biosynthetic pathway. Isopentenyl diphosphate (IPP) and its isomer dimethylallyl diphos-
phate (DMAPP) are synthesized via mevalonate pathway from acetyl-CoA [31]. DMAPP is 
the precursor for the biosynthesis of different and very important isoprenoids like sterols, 
ubiquinones, triterpenoids, and prenylated proteins.
Figure 3. General structures of inhibitors of 24-SMT.
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FPPS catalyzes two sequential steps: the addition of DMAPP to isopentenyl diphosphate 
(IPP) to form geranyl diphosphate (GPP) and the addition of DMAPP to geranyl diphosphate 
to produce farnesyl pyrophosphate (FPP). The inhibition or alteration of FPPS activity can 
regulate the isoprenoid metabolism. Therefore, FPPS has been selected as an excellent target 
for different disorders and anticancer, antibacterial, and antiparasitic drugs design among 
others [32–34].
Bisphosphonates act as inhibitors of bone resorption binding to the bone mineral. They are 
currently used for the treatment of several bone disorders like osteoporosis, Paget’s disease, 
and hypercalcemia [35]. Bisphosphonates were the first FPPS inhibitors known and were 
reported as potent antiparasitic agents. Nitrogen-containing bisphosphonates like pamidro-
nate (16), alendronate (17), risedronate (18), and ibandronate (19) were originally found to 
be effective against T. cruzi without toxicity to the host cells (Figure 5) [36]. Risedronate has 
shown a significantly increased survival of T. cruzi-infected mice in vivo. It was also found 
that diverse bisphosphonate derivatives were effective growth inhibitors of other pathogenic 
trypanosomatids and apicomplexan parasites [32, 37, 38].
Bisphosphonates have the disadvantage that they are highly polar and are rapidly removed 
from the circulatory system. Therefore, more lipophilic derivatives were developed (20) 
[38–40]. Bisphosphonates have a great potentiality as antiparasitic agents with characterized 
mechanisms of action involving the inhibition of FPPS, being very proper candidates to con-
trol and treat American trypanosomiasis. In addition, bisphosphonates have the advantage 
of being inexpensively synthesized and many compounds are FDA-approved drugs for the 
long-term treatment of several diseases.
2.1.5. Squalene synthase (SQS)
Squalene synthase (SQS) is also a key enzyme of ergosterol biosynthesis, which catalyzes 
the condensation of two farnesyl pyrophosphate molecules to form presqualene diphosphate 
and the subsequent loss of diphosphate, rearrangement, and reduction by NADPH to form 
squalene. Then, squalene epoxidase catalyzes the epoxidation of squalene affording oxido-
squalene, which is cyclized by oxidosqualene cyclase to form lanosterol [41, 42]. Therefore, 
Figure 4. Chemical structures of inhibitors of the enzymatic activity of HMG-CoA reductase.
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any of these enzymes constitute an excellent molecular target for antitrypanosomal agent’s 
development. SQS is also under intense study as a possible target for cholesterol-lowering 
drugs in humans [41].
Quinuclidines were developed as cholesterol-decreasing agents but actually, they also turned 
out to be potent SQS inhibitors. However, they showed poor SQS selectivity. It has also been 
reported that this class of compounds eliminated the parasite both in vitro and in vivo [43, 44].
SQ109 (21, Figure 6), an ethylenediamine currently in phase II clinical trials for the treatment 
of tuberculosis, is of great interest for the etiological treatment of Chagas’ disease [45]. Studies 
have conveyed that SQ109 was an inhibitor of dehydrosqualene synthase from Staphylococcus 
aureus, a protein very similar to squalene synthase, suggesting that SQ109 might also inhibit 
T. cruzi SQS [46]. In fact, recently, it was determined that SQ109 is active against all life cycle 
stages of T. cruzi, detecting the most potent activity against the highly infective trypomasti-
gote form. Furthermore SQ109 showed synergism with posaconazole [47].
Other very interesting SQS inhibitors that have been discovered include thiocyanates like 
WC-9 (22), which proved to be a potent inhibitor of this enzyme [48]. Fluorine-containing 
thiocyanate derivatives exhibited higher efficacy as inhibitors of T. cruzi proliferation (23,24) 
(Figure 4) [49]. Recently, the structures of human SQS and T. cruzi SQS bound to a substrate-
like inhibitor were reported suggesting an interesting alternative for the development of 
selective drugs [50].
Figure 5. Chemical structures of representative bisphosphonates targeting FPPS.




Cruzipain is the main cysteine proteinase of T. cruzi, which is essential for the survival of the 
parasite. This enzyme is involved in different cellular functions such as nutrition, penetration 
into the host cell, defense, and differentiation processes [51]. It has been extensively studied as 
a valid target for new drug development [52, 53]. There are several three-dimensional struc-
tures of cruzipain with different inhibitors allowing the identification of structural regions of 
this enzyme that will enable the design of new agents [54, 55].
Numerous structurally varied compounds that inhibit proliferation of T. cruzi by inhibiting 
the enzymatic activity of cruzipain have been reported. Among the compounds tested, K777 
(25), a vinyl sulfone derivative was active against a wide range of susceptible and resistant 
strains (Figure 7). Moreover, it was able to cure T. cruzi acute and non-acute infection in mice, 
showing also synergistic activity with benznidazole [56, 57].
Figure 7. Structures of inhibitors of cruzipain activity.
Figure 6. Chemical structures of inhibitors of the enzymatic activity of squalene synthase.
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Molecules containing thiosemicarbazones have been extensively explored [58–60]. Among 
these, 3, 4-dichlorophenyl thiosemicarbazone (26) is one of the most potent cruzipain inhibi-
tor [61]. Recently, thiazolidinone derivatives (27) were identified as strong antiparasitic com-
pounds (Figure 7) [62, 63].
Benzimidazoles have also been studied as cruzipain inhibitors and various derivatives have 
been synthesized and evaluated. N-(2-(1H-benzo[d]imidazol-2-yl) ethyl)-2-(1-bromonaphtha-
lene-2-yloxy) acetamide (28) was the most potent enzyme inhibitor but it showed moderate 
trypanocidal activity [64, 65].
Other very potent cruzipain inhibitors have been developed such as oxyguanidine deriva-
tives WRR-483, WRR-669, and WRR-676 (29–31). Some of these compounds showed suitable 
metabolic stability and a remarkable trypanocidal activity [66].
Very recently a series of peptidyl nitroalkenes was designed, synthesized, and evaluated as 
cruzipain inhibitors. Several compounds showed high activity against the enzyme observing 
the peptidic nature to be the determinant for their inhibitory activity [67].
Odanacatib (32), clofazimine (33), and benidipine (34) are examples of drug repurposing for 
the development of novel therapeutics for the Chagas’ diseases (Figure 5). Odanacatib is a 
cathepsin K inhibitor used for the treatment of postmenopausal osteoporosis; it is a potent 
cysteine protease inhibitor, which is in Phase III clinical trials [68]. Clofazimine is an antibiotic 
applied to the treatment of leprosy [69] and benidipine is a calcium channel-blocking agent 
employed in the treatment of hypertension [70]. Clofazimine and benidipine were recently 
tested in a murine model of chronic Chagas’ disease infection. Both compounds have reduced 
the parasitemia and the inflammatory effects have been well tolerated [71].
2.3. Trans-sialidase
The enzyme trans-sialidase (TS) belongs to the group of enzymes that are secreted by the para-
site involved in the processes of cell invasion and immune evasion [72]. T. cruzi incorporates 
sialic acid (35) from exogenous sialoglycoconjugates by a trans-glycosylation reaction [73]. 
TS catalyze this transfer from host sialoglycoconjugates to glycoconjugates or mucins, which 
are attached to the cell membrane of T. cruzi via glycophosphatidylinositol anchors [74, 75]. 
Added to its important role, the absence of this enzyme in mammalian organisms makes it an 
excellent molecular target.
Within TS’ inhibitors it can be mentioned fluorinated compounds like 9-benzoyl-3-fluoro-N-
acetylneuraminic acid (36), and 3-fluorosialyl fluoride (37) selectively bind to the active site 
of the enzyme [76]. Sulfonamide-containing hydroxylated chalcones (38) and quinolones (39) 
are also specific inhibitors of T. cruzi TS, being dihydroxylated more potent than monohy-
droxylated derivatives (Figure 8) [77].
Some approved FDA drugs were evaluated on trypomastigotes deriving out of a compu-
tational screening protocol. The anti-inflammatory sulfasalazine (40) showed potent anti-
parasitic effects in in vivo assays, but with moderate TS inhibition. However, this drug and 
sulfonamide-containing compounds could be used as leading drugs in the development of 
new TS inhibitors [78].






 or N1, N8-bis-(glutathionyl)spermidine, (41)) is a dithiol, which is 
responsible for the thiol metabolism in trypanosomatids by maintaining the intracellular 
redox balance [79]. Trypanothione is responsible for the protection against oxidative stress in 
T. cruzi trapping reactive oxygen species [80].
The protective reactions involve two key enzymes, which keep the trypanothione system 
operating: trypanothione reductase (TryR), homologous to mammal glutathione reductase 
and trypanothione synthetase (TryS) [81]. TryR catalyzes the reduction of trypanothione 
disulfide (T[S]
2
, 42) to T[SH]
2
 (Figure 9); TryS catalyzes the synthesis of T[SH]
2
 from glu-
tathione and spermidine, keeping the amount of total trypanothione constant [82]. Taking 
into account the fact that trypanothione system is essential to the survival of parasites, these 
enzymes emerge as valid molecular targets for the search of new chemotherapeutics agents. 
In addition, TryS has no counterpart in mammals, making even more interesting to the design 
more specific and safer inhibitors [2].
Various reports have conveyed that different classes of compounds have selective enzyme 
inhibition activity such as tricyclic ring structures, bicyclic, and heterocyclic compounds or 
polyamines among others.
Figure 9. Structures of the oxidized and reduced forms of trypanothione.
Figure 8. Representative inhibitors of trans-sialidase.
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Mepacrine (43) is a tricyclic antimalarial, which showed TryR inhibition without affecting 
human glutathione reductase and several mepacrine derivatives have been prepared. Although 
these derivatives presented greater potency, they turned out to be toxic to human cells [83].
Tricyclic phenothiazine-containing drugs are currently used as an antidepressant and have 
additionally exhibited antimicrobial activity [84]. Some phenothiazines demonstrated inhibi-
tory activity against TryR [85]. Within them, thioridazine (44) is one of the most potent TryR 
inhibitors as investigations have suggested [86]. Clomipramine (45) [87] is another psychiatric 
drug with inhibiting action towards TryR. Both thioridazine and clomipramine seem to have 
in vivo effects against T. cruzi (Figure 10).
Library screening has allowed the identification of other classes of inhibitors that could be 
useful for the development of more potent TryR inhibitors. Some examples of these com-
pounds are indatraline (46), a monoamine transporter inhibitor, 1-(2-(benzhydryloxy)ethyl)-
4-(3-phenylpropyl)piperazine (GBR-12935, 47) and a benzothiophene-piperidine derivative 
(BTCP 48) [88]. Other or additional, studies allowed finding analogs of these compounds, 
which have increased the potency against TryR exhibiting higher selectivity [89]. The most 
interesting compounds were a piperazine-phenothiazine derivative of GBR-12935 (49) and a 
diaryl sulfide BTCP derivative [50, 88, 90].
Figure 10. Chemical structures of relevant compounds targeting trypanothione reductase.
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Different compounds can behave as TryR inhibitors when turning into reactive radical species 
through the reduction single-electron step [83, 91]. Within these structures, 1, 4 naphthoqui-
nones and nitrofurans have been largely studied [92, 93]. The most potent derivative of 1,4 
naphthoquinone was a quinone–coumarin hybrid [51] despite showing toxicity against rat 
skeletal myoblasts [94].
Between nitrofurans compounds, several 5-nitrofuroic acid derivatives have been synthesized 
and evaluated against T. cruzi. The best compound was 5-nitro-furan-2-carboxylic acid diben-
zyl amide [52], which it significantly increased the trypanocidal nifurtimox activity being 
TryTR your molecular target [95].
3. Conclusions
Currently, the chemotherapy of American trypanosomiasis remains a serious problem in the 
field of neglected tropical diseases. There are no vaccines, and chemotherapy is limited to old 
drugs, which present important drawbacks. Taking into account that this disease is associated 
with poor populations and bad housing conditions, pharmaceutical companies have no eco-
nomic motivations. Therefore, all efforts to the development of new drugs must be made by 
academic and/or governmental institutions and new chemotherapies are needed urgently. In 
order to search new, safer and efficient drugs for the Chagas’ treatment, an overview of pos-
sible molecular targets based on specific features of the biochemistry of Trypanosoma cruzi was 
given. Although there are numerous potentially valid targets, only the more representative 
ones were discussed here. Furthermore, some of the new potential antiparasitic drugs as well 
as drugs applied to other human illness were described in this work. However, despite numer-
ous efforts and progress in the searching of new or repositioned compounds for American 
trypanosomiasis chemotherapy, no ideal drugs are yet available for human treatment
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